Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery
Odyssey Therapeutics Appoints Julie Clauss as Chief Operating Officer and Christopher Butler as SVP, Head of Chemistry
BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the closing of a $101 million Series C financing round led by Ascenta Capital with participation from new and existing investors, including OrbiMed, SR One, General Catalyst, Foresite Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures, BlackMars Capital GmbH, Creacion Ventures, funds and accounts advised by Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, Racing Beach Ventures LLC, The Healthcare Innovation Investment Fund LLC, an investment fund associated with Leerink Partners, Ab Magnitude Ventures, KB Investment, The Global BioAccess Fund, and multiple leading global investors. This Series C financing brings the total capital raised since founding in late 2021 to $487 million. Proceeds will support the advancement of multiple programs into clinical studies and the continuation of investment in discovery to build a sustainable model for therapeutic innovation.
Odyssey Therapeutics has raised a $101 million Series C to help get its next-gen precision immunomodulators and oncology medicines into the clinic.
Odyssey Therapeutics to Present Data for Three Immunology Programs at American College of Rheumatology Convergence 2023
Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer
BOSTON, Nov. 9, 2022 /PRNewswire/ -- Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the appointment of Jeff Hermes, Ph.D., as Executive Vice President of Enabling Sciences and promotion of Natalie Dales, Ph.D., to the newly created position of Chief of Research Operations and Portfolio Strategy. In these roles, Dr. Hermes will oversee capability development and implementation for Odyssey's platform approaches and technologies, and Dr. Dales will drive scientific strategy and facilitate collaboration across the organization.